Scholars Central

Conference abstract

A new technology for DNA vaccination: RALA peptide-mediated gene delivery via dissolving microneedles

Authors: Helen O McCarthy, Ahlam A Ali, Joanne McCaffrey, John W McBride, Adrien Kissenpfennig, Ryan F Donnelly

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cervical cancer has the second highest mortality rate amongst women worldwide, despite the production of recombinant protein HPV vaccines. Limited access in poorer regions, the prophylactic nature of current vaccines and poor patient compliance contribute to a rising incidence. Furthermore, the current vaccine is not effective for those patients with pre-existing HPV lesions. DNA vaccination evokes both therapeutic and prophylactic responses. The bottleneck in the DNA vaccination market lies in an effective delivery technology. The âÂ?Â?solutionâÂ?Â? to this problem is in the two-pronged approach of our technology: (i) a peptide delivery system, termed RALA, that is able to wrap the DNA into nanoparticles, protect the DNA from degradation, enter cells, disrupt endosomes and deliver the DNA to the nucleus and (ii) a microneedle patch (MN) that will house the nanoparticles within the polymer matrix, painlessly breach the skinâÂ?Â?s stratum corneum barrier and dissolve upon contact with skin interstitial fluid thus releasing the nanoparticles into the skin to the antigen presenting cells. Using our novel technology platform we have created a DNA vaccine for cervical cancer in a dissolvable microneedle patch. More specifically the MN patch is loaded with RALA/E6-E7 nanoparticles and this study demonstrates stability, functionality and a prophylactic and therapeutic response to cervical cancer tumours in-vivo. The RALA/E6/E7 nanoparticles were characterized in terms of gel retardation, size and zeta-potential analysis and transmission electron microscopic imaging. The functionality of the RALA/E6-E7 nanoparticles within the polymeric microneedle matrix was assessed by analysis of transfection efficacy in fibroblast NCTC cells via western blot analysis. Cellular toxicity was also assessed via WST-1 assay. C57/BL6 mice were immunized with the RALA-E6/E7 in a prime-boost-boost regimen and blood serum was isolated to measure specific IgG responses and IFN-Ã?³ levels via ELISAs. C57/BL6 mice were also immunised with the MN-RALA/ E6-E7 patches and challenged with cervical cancer. A therapeutic response study was performed in-vivo. Finally the RALA/E6-E7 nanoparticles were lyophilised to increase the dose that can be loaded into the MN patch. Results proved that RALA was essential for stability of the E6-E7 DNA in PVP and that MN-RALA/E6-E7 evokes a more consistent humoral mediated immune response. Tumour challenge studies indicate the MN-RALA/E6-E7 vaccine patch is preventing the uptake of tumours and treating established tumours. Doses greater than 50 Ã?¼g were achieved from a single MN patch. We have, therefore, created a fully functional prototype MN/RALA/E6-E7 DNA vaccine for cervical cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutica Analytica Acta.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutica Analytica Acta
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Helen O McCarthy”
  • BylineArticles whose byline prints “Ahlam A Ali”
  • BylineArticles whose byline prints “Joanne McCaffrey”
  • BylineArticles whose byline prints “John W McBride”
  • BylineArticles whose byline prints “Adrien Kissenpfennig”
  • BylineArticles whose byline prints “Ryan F Donnelly”